Your browser doesn't support javascript.
loading
Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease.
Lafargue, Marie-Camille; Bobot, Mickaël; Rennke, Helmut G; Essig, Marie; Carre, Martin; Mercadal, Lucile; Farhi, Jonathan; Sakhi, Hamza; Comont, Thibault; Golbin, Léonard; Isnard, Pierre; Chemouny, Jonathan; Cambier, Nathalie; Laribi, Kamel; Selamet, Umut; Riella, Leonardo V; Fain, Olivier; Adès, Lionel; Fenaux, Pierre; Cohen, Camille; Mekinian, Arsène.
Afiliación
  • Lafargue MC; Department of Nephrology, Tenon's Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France.
  • Bobot M; Centre de Néphrologie et Transplantation Rénale, AP-HM, Hôpital de la Conception, CHU de la Conception, 13005, Marseille, France.
  • Rennke HG; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Essig M; Department of Nephrology, Assistance Publique-Hôpitaux de Paris, Hôpital Ambroise Paré, Boulogne-Billancourt, Université Paris-Saclay, Paris, France.
  • Carre M; Service d'Hématologie, Centre Hospitalier Universitaire, Grenoble, France.
  • Mercadal L; Department of Nephrology and Renal Transplantation, Assistance Publique-Hôpitaux de Paris, Hôpital de La Pitié Salpêtrière, Paris, France.
  • Farhi J; Maladies du Sang, CHU d'Angers, 49000 Angers, France.
  • Sakhi H; Department of Nephrology and renal transplantation, Necker's Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France.
  • Comont T; Department of Internal Medicine, Institut universitaire du cancer de Toulouse, Centre Hospitalier Universitaire de Toulouse, Université Toulouse III - Paul Sabatier, Toulouse, France.
  • Golbin L; Service de Néphrologie, Dialyse et Transplantation Rénale, CHU Rennes, Hôpital Pontchaillou, Rennes, France.
  • Isnard P; Department of Pathology, Université Paris Cité, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Chemouny J; Hématologie Clinique, Centre Hospitalier de Valenciennes, Valenciennes, France.
  • Cambier N; Department of Haematology, Centre Hospitalier Le Mans, France.
  • Laribi K; Centre Hospitalier Le Mans, Le Mans, France.
  • Selamet U; Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Riella LV; Center of Transplantation Sciences, Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States.
  • Fain O; Hôpital Saint-Antoine, Service de Médecine Interne et de l'Inflammation-(DHU i2B), F-75012, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Adès L; Hématologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, Paris, France.
  • Fenaux P; Hématologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, Paris, France.
  • Cohen C; INSERM U1151 « mechanisms and therapeutic strategies of chronic kidney diseases ¼, Hôpital Necker, Université Paris Cité, Paris, France; Service de Néphrologie et Transplantation rénale, Assistance Publique-Hôpitaux de Paris, Hôpital Necker, Paris, France.
  • Mekinian A; Hôpital Saint-Antoine, Service de Médecine Interne et de l'Inflammation-(DHU i2B), F-75012, Assistance Publique-Hôpitaux de Paris, Paris, France.
Kidney Int Rep ; 8(12): 2733-2741, 2023 Dec.
Article en En | MEDLINE | ID: mdl-38106568
ABSTRACT

Introduction:

Chronic myelomonocytic leukemia (CMML) is a hematologic disorder that is an overlap syndrome between myelodysplastic syndromes and myeloproliferative neoplasms, and can be associated with autoimmune and inflammatory diseases. This study aimed to describe kidney involvement in patients with CMML, their treatments, and outcomes.

Methods:

We conducted a French and American multicenter retrospective study in 15 centers, identifying patients with CMML with acute kidney injury (AKI), chronic kidney disease (CKD), and urine abnormalities.

Results:

Sixteen patients (males, n = 14; median age 76.5 years [71.9-83]) developed a kidney disease 6 months [1.6-25.6] after the diagnosis of CMML. At the time of kidney disease diagnosis, median urinary protein-to-creatinine ratio was 2 g/g [1.25-3.4], and median serum creatinine was 2.26 mg/dl [1.46-2.68]. Fourteen patients (87.5%) underwent a kidney biopsy, and the 2 main pathological findings were lysozyme nephropathy (56%) and renal infiltration by the CMML (37.5%). Ten patients received a new treatment following the CMML-associated kidney injury. Among patients with monitored kidney function, and after a median follow-up of 15 months [9.9-34.9], 4 patients had CKD stage 3, 4 had CKD stage 4, 1 had an end-stage kidney disease. In our patient series, 2 patients evolved to an acute myeloid leukemia (AML), and 5 died. Compared with 116 CMML controls, patients who had a kidney involvement had a higher monocyte count (P < 0.001), had more CMML-1 (P = 0.005), were more susceptible to develop an AML (P = 0.02), and were more eligible to receive a specific hematologic treatment, with hydroxyurea, or hypomethylating agents (P < 0.001), but no survival difference was seen between the 2 groups (P = 0.6978).

Conclusion:

In this cohort of patients with CMML with a kidney injury, the 2 most frequent renal complications were lysozyme-induced nephropathy and renal infiltration by the CMML. Kidney involvement should be closely monitored in patients with CMML.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Kidney Int Rep Año: 2023 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Kidney Int Rep Año: 2023 Tipo del documento: Article País de afiliación: Francia